Active Ingredient(s): Cobimetinib
FDA Approved: * November 10, 2015
Pharm Company: * GENENTECH INC
Category: Cancer

Cobimetinib, sold under the brand name Cotellic, is an anti-cancer medication used in combination with vemurafenib (Zelboraf) alone or with both vemurafenib and atezolizumab (Tecentriq) to treat melanoma.[1][5] Cobimetinib is a MEK inhibitor.[1] Cotellic, Zelboraf, and Tecentriq are all marketed by Genentech, a subsidiary of Roche.[1][5][6] The most common side effects include diarrhea, rash, nause... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Cotellic 20 mg Oral Tablet, Film Coated
NDC: 50242-717
Genentech, Inc.
Cobimetinib Fumarate
NDC: 71973-717
Delpharm Milano Srl